Extra-hepatic metabolism of xenobiotics by epithelial tissues has evolved as a selfdefence mechanism but has potential to contribute to the local activation of carcinogens. Bladder epithelium (urothelium) is bathed in excreted urinary toxicants and pro-carcinogens. This study reveals how differentiation affects cytochrome P450 (CYP) activity and the role of NADPH:P450 oxidoreductase (POR). CYP1A1 and CYP1B1 transcripts were inducible in normal human urothelial (NH5U) cells maintained in both undifferentiated and functional barrier-forming differentiated states in vitro. However, ethoxyresorufin O-deethylation (EROD) activity, the generation of reactive BaP metabolites and BaP-DNA adducts, were predominantly detected in differentiated NHU cell cultures. This gain-of-function was attributable to the expression of POR, an essential electron donor for all CYPs, which was significantly upregulated as part of urothelial differentiation. Immunohistology of muscle-invasive bladder cancer (MIBC) revealed significant overall suppression of POR expression. Stratification of MIBC biopsies into "luminal" and "basal" groups, based on GATA3 and
cytokeratin 5/6 labeling, showed POR over-expression by a subgroup of the differentiated luminal tumors. In bladder cancer cell lines, CYP1-activity was undetectable/low in basal POR lo T24 and SCaBER cells and higher in the luminal POR over-expressing RT4 and RT112 cells than in differentiated NHU cells, indicating that CYP-function is related to differentiation status in bladder cancers. This study establishes POR as a predictive biomarker of metabolic potential. This has implications in bladder carcinogenesis for the hepatic versus local activation of carcinogens and as a functional predictor of the potential for MIBC to respond to prodrug therapies. The aryl-hydrocarbon receptor (AHR) is a transcription factor expressed constitutively by many epithelial tissues. In epidermal keratinocytes, AHR-mediated transcription has been implicated in differentiation, 2 although AHR is better known for regulating expression of a battery of CYP genes (including CYP1A1, CYP1A2, and CYP1B1) as part of Phase I metabolism in the detoxification of xenobiotics. CYP1-mediated metabolism is particularly important for aromatic amines, which include the bladder pro-carcinogens 2-naphthylamine and 4-aminobiphenyl, and polycyclic aromatic hydrocarbons (PAH), including benzo[a]pyrene (BaP; reviewed in Ref. 3 ). Phase I metabolism of xenobiotics by CYPs is often the first step in detoxification as it supports the Phase II conjugation reactions.
However, Phase I metabolites are frequently reactive and studies have shown CYP1 enzyme function to be activating in the case of PAH procarcinogens. 4 CYP1A1, CYP1B1, and the AHR nuclear translocator (ARNT) have been identified as potential risk factors for human bladder cancer through association of single nucleotide polymorphisms (SNPs) with the disease, 5,6 but a robust case is lacking and it remains unclear whether the SNPs affect production of genotoxicants solely in the liver, or whether extra-hepatic metabolism is involved.
Bladder cancer has a high prevalence of somatic mutations, a trait shared with cancers where chronic mutagen exposure plays a causal role (such as lung cancer and melanoma). 7 Smoking is the main risk factor for bladder cancer with a hazard ratio of 2.33 for former smokers and 4.27 for current smokers. 8 Following PAH exposure, incomplete hepatic metabolism leads to the excretion of bladder pro-carcinogens in the urine 9 where urothelial CYP-activity could lead to DNA adduct formation and ultimately mutation. BaP is the major PAH in cigarette smoke and the bladder tissue of current smokers contains bulky DNA adducts. 10 Acting in combination with microsomal epoxide hydrolase (EPHX1), the bioactivation of BaP to species capable of forming DNA adducts is performed most efficiently by CYP1A1 and CYP1B1. 11 Studies of Cyp1-knockout mice suggest Cyp1a1 is essential for detoxification of BaP in the epithelium of the gastrointestinal tract, but the bladder remains unstudied (reviewed in Ref. 12 ). CYP activity is driven by electron donation from the NADPH:CYP oxidoreductase (POR) and abundance of POR determines metabolic capacity in the CYP system. 13, 14 POR is one member of the diflavin oxidoreductase family (nitric oxide synthase is the other) and is not specifically a reductase for the CYPs but can donate electrons to heme oxygenase among other enzymes (reviewed in Ref. 15 ). POR expression in normal and neoplastic urothelium of humans remains unquantified, although a SNP was recently associated with increased bladder cancer risk. 16 Since the first report of CYP1 activity in rabbit bladders in 1985, 17 there has only been fragmented study of AHR-mediated metabolism in the urinary tract. Studies of non-transformed cells have used either normal porcine urothelial cells (which demonstrate no ethoxyresorufin O-deethylation (EROD), a measure for CYP1 enzyme activity) 18 or human cells cultured from urinary sediments (which most likely originate from the kidney), 19 limiting their relevance to human urothelium. It is therefore timely to establish whether CYP1 enzymes function in human urothelium and whether there is sufficient capacity to activate potential bladder carcinogens.
Normal (non-neoplastic) human urothelium is not available in the quantities required to generate microsomes for the study of enzyme activity. The aim of this study was to establish the potential of bladder CYP1 metabolism; using in vitro cell culture models representing normal and neoplastic human urothelium in undifferentiated and differentiated states (reviewed in Ref. 20 21 For the studies described here, 15 independent cell lines were used between passages one and five. In the figures, each independent donor NHU cell line used has been given a unique symbol consistent between every panel (including supplementary).
Differentiation of in vitro-propagated NHU cell cultures into
barrier-forming stratified urothelial cell sheets was performed as described in detail elsewhere. 22 Briefly, NHU cells propagated in KSFMc were preconditioned for 5 days in 5% adult bovine serum (ABS) before harvesting and reseeding in same. After 24 h, the exogenous calcium concentration was increased to near-physiological (2 mM) and cultures were maintained for 7 days before performing assays. A tissue microarray (TMA) was constructed from formalin-fixed paraffin wax-embedded MIBC biopsies, exactly as described 24 using tumor biopsies obtained from 61 non-consecutive patients who underwent radical cystectomy for muscle-invasive urothelial carcinoma of the urinary bladder in the Department of Urology, Regensburg University Medical Center, between 1998 and 2008.
Median patient age was 71 (range: 55-87) years. Eighty-one percent of patients were male. Surgical specimens were assessed histopathologically by a single expert uropathologist for grading and staging based on the criteria of the 1973 WHO classification and 2010 TNM system. 25, 26 Clinical characteristics of the patients are summarized in Supplementary Table S1. 1.5-mm donor tissue cores were used, and the representativeness of the TMA was confirmed histopathologically by comparing the TMA and the original tissue sections for each tumor.
Immunoperoxidase labeling of the MIBC TMAs was performed on 4-μm sections mounted on poly-L-lysine-coated glass slides and compared to a "normal" control group of bladders (non-trigone coldcut biopsies) with no history of bladder malignancy. These tissues were from patients biopsied for a range of conditions including prostate cancer, stress incontinence, overactive bladder, and cystitis, some of which have been described previously. 27 
| Indirect-immunofluorescent labeling
To generate differentiated NHU cell cultures for immunolabeling, NHU cells preconditioned for 5 days in 5% ABS were passaged and seeded onto glass 12-well slides at 3 × 10 4 cells/well. After 24 h the calcium concentration was raised to 2 mM and the cultures maintained for 7 days, before treatment with ITE or a vehicle control. After 16 h, slides were fixed in methanol:acetone (1:1) for 30 s, air dried and rabbit anti-AHR affinity-purified polyclonal antibody was applied overnight at 4°C (1:500 dilution; Enzo Life Sciences, BML-SA210). Unbound primary antibody was removed by washing in PBS and secondary antibody (Alexa-594, Molecular Probes) was applied for 1 h at ambient temperature. Slides were washed in PBS, with 0.1 μg/mL Hoechst 33258 added to the penultimate wash, before mounting in antifade mountant and visualization by epifluorescence on a BX60 microscope (Olympus).
Analysis was performed on images collected at a fixed exposure using TissueQuest Software (Tissue Gnostics).
| Western blotting
Twenty micrograms of whole cell protein lysate was loaded into each gel track for electrotransfer to PVDF membranes with the full method provided in Supplementary Methods. The test antibodies used were anti-AHR (1:2000, rabbit, Enzo Life Sciences, BML-SA210), anti-CYP1A1 (1:4000, rabbit, generous gift from Prof. F. Peter Guengerich, Vanderbilt University), anti-POR (1:10 000, rabbit "CH60" a kind gift from Prof. Roland Wolf and Dr Colin Henderson, Dundee University). 28 Homogeneous loading and transfer were evaluated using a β-actin antibody (Sigma, Clone AC15, Mouse, 1:10 000 dilution).
Detection of CYP1A1 and GAPDH protein was performed exactly as described. 29 Densitometry was performed in all cases using Im age Studio Lite Ver 5.0 software (LI-COR). Cropped Western blots are shown in the main figures with full blots provided as Supplementary Figures S1 and S2.
| Reverse transcribed-quantitative polymerase chain reaction (RT-qPCR)
Method and primers are provided in Supplementary Materials.
| Ethoxyresorufin O-deethylation (EROD) activity assays
EROD activity assays, used as a measure for CYP1 enzyme activity, were performed as described in detail elsewhere 30 with minor modifications to convert the assay for black-walled collagen-coated glass coverslip- 
| High performance liquid chromatography (HPLC) analysis of BaP metabolites
Culture medium from confluent 10 cm dishes of NHU cells was collected on ice, centrifuged at 4°C for 5 min at 300g and stored at authentic standards which were synthesized as described. 29 
| 32 P-postlabeling of BaP-DNA adducts
Following collection of the medium, cultures were washed twice in cold D-PBS (Gibco), scraped in 1 mL PBS, centrifuged at 800g for 5 min at 4°C and dry cell pellets were stored at −80°C until analysis. DNA was isolated from BaP-treated cells using a standard phenol/chloroform extraction method. BaP-DNA adduct formation was determined using the nuclease P1 digestion enrichment version of thin-layer chromatography (TLC) and 32 P-postlabeling assay was carried out as described. 31 Briefly, DNA samples (4 µg) were digested with micrococcal nuclease (288 mU; Sigma) and calf spleen phosphodiesterase (1.2 mU; MP Biomedical) and then enriched and labeled. Solvent conditions for the resolution of 32 P-labeled adducts on polyethyleneimine-cellulose TLC were as described. 31 Subsequently, TLC sheets were scanned using a Packard Instant Imager (Dowers Grove, IL) and DNA adducts (RAL, relative adduct labeling) were quantified from the adduct counts per minute (cpm), the specific activity of [γ- 32 nucleotides. An external BPDE-DNA standard 32 was employed for identification of adducts in experimental samples. 
| Immunoperoxidase labeling

| Statistical analysis
Data were assessed for statistical significance using InStat 3 or Prism 6 software (Graphpad). On all graphs statistical significance is represented as follows; *P < 0.05, **P < 0.01, and ***P < 0.001.
| RESULTS
| AHR in urothelial differentiation
AHR protein was detected in similar abundance in both undifferentiated and differentiated NHU cell cultures ( Figure 1A) . AHR protein was observed to be widely distributed throughout the cell in differentiated NHU cells treated with a vehicle control; however, following exposure to 1 μM ITE for 16 h, AHR was significantly more abundant in the nucleus ( Figures 1B and 1C ). cultures; Supplementary Figure S1 and Supplementary Methods).
| Induction of CYP1A1 and CYP1B1 transcripts by AHR
The effect of the endogenous AHR ligand "ITE" on CYP1 gene expression was studied in NHU cell lines from six independent donors. Significant (P ≤ 0.001) induction of CYP1A1 and CYP1B1 transcripts was observed in response to ITE in both undifferentiated (30 and 49-fold, respectively) and differentiated (23 and 19-fold, respectively) cultures compared to their respective vehicle controls ( Figure 1D ). Differentiated NHU cells showed preferential upregulation of CYP1A1 transcript, while undifferentiated cells induced CYP1B1 to a greater extent (Supplementary Figure S4 ).
Differentiation of NHU cells itself induced a smaller increase in CYP1A1
and CYP1B1 transcript expression (4.1 and 1.5-fold, respectively; Figure 1D ). No expression of CYP1A2 transcript was detected in NHU cells (data not shown).
| Induction of EROD activity in NHU cells by AHR
Basal EROD activity was barely detectable in NHU cells and was not inducible in undifferentiated NHU cells (Figure 2 ). EROD activity was rapidly induced in differentiated NHU cells by 1 μM ITE, with effects apparent by 8 h and a peak of activity at 16 h (mean 55-fold increase, Figure 2 ). After 16 h (without replenishment of ITE), EROD activity in differentiated NHU cells began returning to baseline (Figure 2 ).
| Inhibition of EROD activity by TMS
EROD can be performed by all CYP1 family members with varying degrees of efficiency. 34 As no CYP1A2 transcript expression was observed in the urothelium, this enzyme was ruled out. Following a 16 h treatment with 1 μM ITE, induced CYP1 enzyme activity was inhibited by TMS in differentiated NHU cells from three donors with a mean IC 50 of 6.9 μM ( Figure 3A) . To further characterize the inhibition RT-qPCR showed BaP exposure did not induce CYP1 transcripts in undifferentiated NHU cells but did significantly in differentiated cultures (Supplementary Figure S5A ). This result was confirmed for CYP1A1 at the protein level, where BaP exposure did not induce CYP1A1 expression in undifferentiated NHU cells, but did significantly in the differentiated cultures ( Figure 4) . No specific antibody could be found to support CYP1B1 detection.
| CYP1A1 and POR Western blotting before and after BaP exposure
Western blotting for POR established that abundance was not affected by ITE, TMS, or BaP exposure; but was elevated by differentiation of NHU cells (mean 2.1-fold; Figure 4 ). RT-qPCR of POR transcript confirmed differentiation of NHU cells from three Figure S5B ).
| BaP metabolism
Cell lines established from three independent donors were monitored before (EROD, Figure 5A ) and after BaP treatment (HPLC and 32 P-postlabeling, Figure 5B-D) . Monitoring ERODactivity prior to BaP exposure confirmed significant induction of CYP1-function in all three independent cell lines (mean 42-fold) and showed that TMS provided significant inhibition of enzyme function in differentiated NHU cells (mean 14% of ITE-induced activity, Figure 5A ).
To establish whether urothelial CYP1 was capable of activating the known carcinogen BaP, cultures were exposed for 6 h and metabolites were measured in the culture medium by HPLC ( Supplementary Figure S6) . First, CYP1A1 oxidizes BaP to an epoxide Figure 5B) and BaP-tetrol-I-1 ( Figure 5C ). The formation of BaP metabolites mirrored the trends observed for EROD-activity ( Figure 5A ); with metabolism greatest in differentiated NHU cell cultures, inducible by pre-treatment with ITE (2.7 and 4.1-fold for dihydrodiol and tetrol, respectively) and inhibited by TMS (to 46% and 35% for dihydrodiol and tetrol, respectively; Figures 5B and 5C ).
The presence of BaP-tetrol-I-1 in the medium of NHU cell cultures ( Figure 5C ) suggested that BPDE might also be forming the pre-mutagenic DNA adducts (ie, 10-(deoxyguanosin-N 2 -yl) -7,8,9-trihydroxy-7,8,9,10- tetrahydrobenzo[a]pyrene; ["dG-N 2 -BPDE"] that have previously been observed in vitro and in vivo. 14 Figure S7) .
No DNA adducts were detected in control (untreated) samples.
Pre-treatment of differentiated NHU cells with 1 μM ITE significantly increased BaP-DNA adduct levels compared to controls (3.7-fold) and 12 μM TMS significantly reduced this (to 21% of induced levels; Figure 5D ). While the changes were not statistically significant, dG-N 2 -BPDE adducts were formed in undifferentiated NHU cell cultures and adduct levels were both increased by ITE pre-treatment and inhibited by TMS ( Figure 5D ). The correlation between EROD-activity and BaP-DNA adduct levels in the same three cell lines had an R 2 = 0.757 (Supplementary Figure S8 ).
| Xenobiotic metabolism in bladder cancer
Immunoperoxidase labeling of MIBC showed significant (P < 0.05) reduction in mean POR expression when compared to normal nonneoplastic bladder urothelium (Figure 6 A) Figure S11 ). As a model of the POR over-expressing tumors ( Figures 6A and 6C) , the well-differentiated/luminal (Supplementary Figure S10 ) RT4 and RT112 bladder cancer cell lines showed 1 μM ITE-inducible EROD-activity ( Figure 6D ). Mean peak EROD activity at 16 h was 60.0, 89.3, and 83.3 nM resorufin/min/mg for differentiated NHU, RT4 and RT112 cells, respectively ( Figure 6D ).
| DISCUSSION
This study provides experimental and clinical evidence that CYP-activity by normal urothelium is reliant on the differentiation-dependent expression of POR, thereby defining the CYP-capacity of different total CYP-mediated metabolism in mice, 14 and combined with this study suggests POR can be used as a biomarker of total CYP-capacity in tissues. MIBC showed an overall suppression of POR; this was exemplified by the basal-type T24 and SCaBER cell lines, which showed no EROD-activity even though CYP1 transcripts were inducible (Supplementary Figure S11 ), suggesting an overall loss of functional CYP-activity in basal MIBC. By contrast, a subset of MIBC was identified that over-expressed POR relative to normal bladder urothelium. In our series, this subgroup defined 16.6% of the luminal tumors. Using RT4 and RT112 cells as representative luminal POR over-expressing bladder cancer cell lines, it was confirmed that these cells showed greater induced peak metabolic activity than achieved by differentiated NHU cells. These observations are important in associating functional, drugmetabolizing activity to histologically-defined tumor sub-groups. Several FIGURE 3 (A) Differentiated NHU cells treated for 16 h with 1 μM ITE were assessed for EROD activity in the presence of increasing concentrations of the specific CYP1 inhibitor TMS. Linear regression had an R 2 of 0.99 and the IC 50 was 6.9 μM. Results are presented as mean ± SD (n = 3 independent donor cell lines with six replicates per donor). (B) Differentiated NHU cells treated for 16 h with 1 μM ITE were exposed to varying concentrations of ethoxyresorufin and TMS to generate a Lineweaver-Burk plot. The experiment was repeated in three independent donor cell lines; this figure shows representative data from a single donor, values are the mean of duplicates. Trend-lines were derived from Michaelis-Menten fitted data. (C) The Ki for TMS against differentiated NHU cell EROD activity was estimated as 0.26 μM by identifying the X-axis intersect of the Km/Vmax trendline CYP1-activated therapies are in development to target epithelial tumors [35] [36] [37] and POR is thought to be critical to the activation of some hypoxia-activated prodrugs, 38 offering potential for future trials targeting the POR hi group of MIBC patients we report here.
The evidence presented here for CYP1A1 function in human urothelium and its role in BaP metabolism builds on earlier work showing BaP metabolism by organ cultures of human bladder tissue. 39, 40 These earlier studies demonstrated that the tissue had capacity to metabolize BaP, but without confirming the cell type responsible due to the heterogeneous nature of the cell types present.
In particular, it was noted that the bladder was the most active BaP metabolizer of all the human explant tissues tested at that point. 40 Our study has shown CYP1A1 and CYP1B1 transcript expression by human urothelium and confirmed CYP1A1 protein, although no suitable antibody could be found for CYP1B1. Studies of purified enzymes show that CYP1A1 is more efficient at EROD (12-fold) and
BaP hydroxylation (2-7-fold) than CYP1B1. 34, 41 Based on the greater induction of transcript in NHU cells and the greater efficiency of CYP1A1 to perform the reactions studied here, we believe that CYP1A1 is the critical enzyme in urothelial activation of BaP.
The potential for activation of pro-carcinogens by human urothelium observed in this study provides a local mechanism for SNPs previously linked to bladder cancer (CYP1A1, CYP1B1, and ARNT 5,6 and, more recently, POR). 16 Despite strong evidence for the association of smoking and occupational BaP exposure with bladder cancer and the support in this study for urothelial activation of PAHs, the smoking-associated mutational signature seen in lung cancer has not been observed in bladder cancer. 7, 42 This may be due to the tissuespecific nature of extra-hepatic CYP activity (reviewed in Ref. 1 No evidence was found to support a role for AHR in urothelial cytodifferentiation, which is known to be primarily driven by peroxisome proliferator-activated receptor γ (PPARγ). 44 By contrast, adipocyte differentiation is also mediated by PPARγ and during that process AHR expression is lost 45 suggesting a functional maintenance of AHR by differentiated urothelium.
FIGURE 4
Western blotting of CYP1A1 normalized to GAPDH; and POR normalized to β-actin in NHU cell cultures. CYP1A1 was significantly inducible in undifferentiated cells and differentiated cultures (4.9 and 5.0-fold; P < 0.05 and P < 0.001, respectively) but reached significantly greater ITE-induced abundance in differentiated cells (1.9-fold P < 0.01). BaP exposure alone did not induce CYP1A1 expression in undifferentiated cells but did significantly in differentiated cultures (4.2-fold; P < 0.001). POR expression was on average 2.2-fold (P < 0.01) higher in differentiated cultures, but did not respond significantly to either ITE or BaP exposure. Results are presented as mean ± SD (n = 3 independent donor cell lines) with significance in expression assessed by ANOVA with Tukey-Kramer post-test. Representative Western blots shown from single donor. N/A, not applicable
To what extent urothelial (rather than hepatic) metabolism generates the mutagens that drive cancer initiation remains to be established in future studies. However, the temptation to resort to in vivo studies is flawed by the poor homology between human CYP1A1 protein and the rat/mouse/pig orthologs in the BaP interacting region (80.6%, 80.9%, and 82.5%, respectively; Supplementary Figure S12 ). In particular, Asn-222 of CYP1A1 has evolved as a negatively charged aspartic acid in rats, mice, and pigs. Asn-222 lies centrally in the five- In differentiated NHU cells EROD was induced by 16 h 1 μM ITE pre-treatment (42-fold; P < 0.001) and inhibited to 14% of peak activity by 12 μM TMS (P < 0.0001). n = 3 independent donor cell lines; six replicate experiments per donor. (B) HPLC analysis of BaP-7,8-dihydrodiol in NHU cultures exposed to 2 μM BaP for 6 h. A total of 1 μM ITE pre-treatment of differentiated NHU cells significantly increased the abundance of BaP-7,8-dihydrodiol in the culture medium compared to controls (2.7-fold; P < 0.05) and 12 μM TMS reduced this to 46% (not significant). n = 3 independent donor cell lines; duplicate replicate experiments per donor. Representative chromatograms of the HPLC analysis are shown in Supplementary Figure 4 . (C) HPLC analysis of BaP-tetrol-I-1 in NHU cultures exposed to 2 μM BaP for 6 h. A total of 1 μM ITE pre-treatment of differentiated NHU cells significantly increased the abundance of BaP-tetrol in the culture medium compared to controls (4.1-fold; P < 0.01) and 12 μM TMS significantly reduced this to 35% of induced levels (P < 0.05). Results are presented as mean ± SD (n = 3 independent donor cell lines; duplicate replicate experiments per donor). Representative chromatograms of the HPLC analysis are shown in Supplementary Figure 4 . (D) 32 P-postlabeling analysis of BaP-DNA adducts in NHU cultures exposed to 2 μM BaP for 6 h. A total of 1 μM ITE pre-treatment of differentiated NHU cells significantly increased the number of dG-N 2 -BPDE adducts per 10 8 nucleotides compared to controls (3.7-fold; P < 0.001) and 12 μM TMS significantly reduced this (to 21% of induced levels; P < 0.001). n = 3 independent donor cell lines; duplicate experiments per donor. Representative autoradiograms showing the DNA adduct profiles obtained by 32 P-postlabeling are shown in Supplementary Figure S5 . For all panels, results are presented as mean ± SD, significance was assessed by ANOVA with Tukey-Kramer posttests and cell lines from the same three donors were used for all graphs/biological end-points BAKER ET AL. | 615 residue disruption of helix F that is unique to CYP1A1 and appears to modulate substrate movement, binding, and orientation. 46 In addition, Asn-222 is thought to be within 5Å of BaP when bound by CYP1A1 and involved in an extensive hydrogen bonding network that stabilizes the binding pocket. 46 Taken together with the differences in rodent urinary tract physiology, with short duration of urinary storage, differences in urothelial cell cycle regulation and a low threshold for cancer initiation, 47 this limits the validity of extrapolating rodent in vivo studies to humans. In this study, a more direct human line of evidence was pursued from 2D cultures of normal and malignant urothelium, via organoids to primary MIBC, offering an alternative route to the in vitro-in vivo paradigm.
FIGURE 6
Analysis of NADPH:P450 oxidoreductase (POR) expression and CYP-activity in bladder cancer. (A) Immunoperoxidase labeling of POR was quantified in a group of "normal" non-neoplastic bladders (n = 16) and compared with muscle-invasive bladder cancer (MIBC; n = 59) and organoid models of bladder cancer selected to represent POR suppressed (T24 and SCaBER) and over-expressing (RT4 and RT112) tumors. MIBC showed significant (P < 0.05, Mann-Whitney U-test) suppression of mean POR expression; however, a group of outliers was noted which over-expressed POR (open circles, representing 11.9% of cases). (B) Classification of MIBC as either luminal or basal based on quantification of GATA3 and KRT5/6 immunoperoxidase labeling was performed according to Dadhania et al 33 , reproducing the logistic regression analysis (LRA) and support vector machine (SVM) cut-off lines derived in that study. All POR over-expressing tumors (red circles) were classified as the more differentiated luminal type of MIBC. (C) Micrographs illustrating the POR immunoperoxidase labeling of normal bladder, MIBC, and cancer cell line (RT4, RT112, T24, and SCaBER) organ culture samples described in panel A. Scale bar represents 50 μm and applies to all images. (D) T24 and SCaBER cells generated peak EROD-activity of 1.6 and 19.5 nM resorufin/min/mg, respectively following ITE exposure. By contrast, 1 μM ITE-induced a peak EROD-activity of 89.3 and 83.1 nM resorufin/min/mg in the POR overexpressing RT4 and RT112 cell lines, respectively. RT4 and RT112 EROD was significantly higher than the mean of 60.0 nM resorufin/min/mg observed for differentiated NHU cells (n = 8 donors; each data point is the mean of six replicate cultures per donor) It has been thought for decades that the metabolism of procarcinogens occurred in the liver and that bladder cancer was caused by the hydrolysis of conjugated metabolites in the urine or by enzymatic deconjugation in the urothelium. This study demonstrates the capacity of functionally-differentiated normal human urothelium to activate the pro-carcinogen BaP locally to active intermediates capable of forming DNA adducts (ie, dG-N 2 -BPDE). The relative contributions of hepatic and urothelial metabolism to carcinogen activation should be re-evaluated to better understand their relative roles in bladder cancer initiation. Furthermore, the association between differentiation and xenobiotic metabolism is maintained in a sub-group of PORoverexpressing luminal MIBC of predicted high metabolic potential, suggesting these patients as candidates for prodrug therapies.
